Intetics CEO Boris Kontsevoi Highlights the Success Potential of Conversational AI in Business
NAPLES, Fla., June 27, 2023 (GLOBE NEWSWIRE) — Boris Kontsevoi is a technology executive, President…
News
Datametrex Cancels Investor Relations Agreement and Grant of Options
Toronto, Ontario–(Newsfile Corp. – June 27, 2023) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB:…
All Comcast NBCUniversal LIFT Labs Generative AI Accelerator Participants Secure Partnerships with Comcast, NBCUniversal, or Sky
Six-week immersive program featuring eight founders concludes with a Generative AI Summit PHILADELPHIA–(BUSINESS WIRE)–Today, Comcast…
Trinity Hunt Partners Acquires Digital Marketing Company REQ
Washington, DC-based REQ will support THP’s vision to rapidly scale through strategic investments to create…
Esker To Pay €0.75 per Share As Dividend for 2022, Up 25%, Affirming Growth Momentum for 2023
Long-standing shareholders to receive a 10% bonus LYON, France & MIDDLETON, Wis.–(BUSINESS WIRE)–Esker, a global…
KBRA Releases Research – CMBS Loan Performance Trends: June 2023
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA releases a report on U.S. commercial mortgage-backed securities (CMBS) loan performance trends…
LifeArc strengthens Board of Trustees with new appointments
LifeArc strengthens Board of Trustees with new appointments 27 June 2023: LifeArc, the self-funded medical…
LifeArc strengthens Board of Trustees with new appointments
LifeArc strengthens Board of Trustees with new appointments 27 June 2023: LifeArc, the self-funded medical…
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
– U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic…
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
– U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic…
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient…
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient…
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend…
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend…
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all…
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all…
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies…
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies…